# US 2024/0200105 A1 · Gene expression regulatory system using crispr system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200105 A1
- Document ID: US20240200105A1
- Status: Published application
- Kind: A1
- Application number: 18/287,118
- Filed: 2022-04-08
- Published: 2024-06-20
- Earliest claimed: 2021-04-16
- Assignees: Genkore Inc.
- Applicants: Genkore Inc.
- Inventors: Yong-Sam KIM; Do Yon KIM; Hyun Jung CHIN; Dongmin JEONG; Jeong Heon KO
- Web page: https://patentgrep.com/patent/US20240200105A1

## CPC

- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/907: {in mammalian cells}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/095: containing a nuclear export signal
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A CRISPR regulatory system is disclosed. More particularly, the CRISPR regulatory system is useful for effectively regulating expression of a target gene and contains a Cas12f1 fusion protein and an engineered Cas12f1 guide RNA Uses of the CRISPR regulatory system are also disclosed. A method of regulating expression of a target gene by using a CRISPR regulatory system containing a Cas12f1 fusion protein and an engineered Cas12f1 guide RNA is also disclosed.

## Claims

### Claim 1

A gene expression regulatory composition for inhibiting expression of a target gene, the composition comprising:
a transcriptional inhibitor Cas12f1 fusion protein or a nucleic acid encoding the transcriptional inhibitor Cas12f1 fusion protein, and
an engineered Cas12f1 guide RNA or a nucleic acid encoding the engineered Cas12f1 guide RNA,
wherein the transcriptional inhibitor Cas12f1 fusion protein comprises a dead Cas12f1 (dCas12f1) protein and a transcriptional inhibitor protein,
wherein the dCas12f1 protein is a modified form of a wild-type Cas12f1 protein in which aspartic acid (D) which is the 326th amino acid, glutamic acid (E) which is the 422nd amino acid, arginine (R) which is the 490th amino acid, or aspartic acid (D) which is the 510th amino acid in the amino acid sequence constituting the wild-type Cas12f1 protein is substituted with alanine (A), glutamine (Q), leucine (L), tryptophan (W), or valine (V), and
the transcriptional inhibitor protein is a protein or peptide that inhibits or suppresses transcription of the gene, and
wherein the engineered Cas12f1 guide RNA comprises:
an engineered scaffold region;
a spacer, and
a U-rich tail,
wherein the engineered scaffold region, the spacer, and the U-rich tail are sequentially linked to each other in a 5′ to 3′ direction,
the spacer comprises 10 to 50 nucleotides, and has a sequence complementary to the target sequence,
a sequence of the U-rich tail is represented by (UaN)bUc, wherein N is one of adenosine (A), uridine (U), cytidine (C), and guanosine (G), and a, b, c are each an integer, with a being between 1 to 5 inclusive, and b being 0 or greater,
a sequence of the engineered scaffold region is different from 5′-CUUCACUGAUAAAGUGGAGAACCGCUUCACCAAAAGCUGUCCCUUAGGGGAUUAGA ACUUGAGUGAAGGUGGGCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUCUU CGGAAAGUAACCCUCGAAACCAAAUUCAUUUGAAAGAAUGAAGGAAUGCAAC-3′ (SEQ ID NO: 7), and
the sequence of the engineered scaffold region is such that the following sequences are sequentially linked to each other in a 5′ to 3′ direction:
a sequence selected from the group consisting of 5′-A-3′, 5′-AA-3′, 5′-GAA-3′, 5′-AGAA-3′, 5′-GAGAA-3′, 5′-GGAGAA-3′, 5′-UGGAGAA-3′, 5′-GUGGAGAA-3′, 5′-AGUGGAGAA-3′, 5′-AAGUGGAGAA-3′ (SEQ ID NO: 17), 5′-AAAGUGGAGAA-3′ (SEQ ID NO: 18),
5′-UAAAGUGGAGAA-3′ (SEQ ID NO: 19),
5′-AUAAAGUGGAGAA-3′ (SEQ ID NO: 20),
5′-GAUAAAGUGGAGAA-3′ (SEQ ID NO: 21),
5′-UGAUAAAGUGGAGAA-3′ (SEQ ID NO: 22),
5′-CUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 23),
5′-ACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 24),
5′-CACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 25),
5′-UCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 26),
5′-UUCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 27), and
5′-CUUCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 10);
a sequence selected from the group consisting of 5′-G-3′, 5′-UUAGG-3′, 5′-CUUAGGG-3′, 5′-CUUAGUGG-3′, 5′-CCUUAGGUGG-3′ (SEQ ID NO: 342), 5′-CCGUUAGGUGG-3′ (SEQ ID NO: 343), 5′-CCGCUUAGGGUGG-3′ (SEQ ID NO: 344),
5′-CCGCUUUAGAGGUGG-3′ (SEQ ID NO: 345),
5′-CCGCUUUUAGAAGGUGG-3′ (SEQ ID NO: 346),
5′-CCGCUUCUUAGGAAGGUGG-3′ (SEQ ID NO: 347),
5′-CCGCUUCAUUAGUGAAGGUGG-3′ (SEQ ID NO: 348),
5′-CCGCUUCACUUAGGUGAAGGUGG-3′ (SEQ ID NO: 349),
5′-CCGCUUCACUUAGAGUGAAGGUGG-3′ (SEQ ID NO: 350),
5′-CCGCUUCACCUUAGGAGUGAAGGUGG-3′ (SEQ ID NO: 351),
5′-CCGCUUCACCAUUAGUGAGUGAAGGUGG-3′ (SEQ ID NO: 352),
5′-CCGCUUCACCAAUUAGUUGAGUGAAGGUGG-3′ (SEQ ID NO: 353),
5′-CCGCUUCACCAAAUUAGCUUGAGUGAAGGUGG-3′ (SEQ ID NO: 354),
5′-CCGCUUCACCAAAAUUAGACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 355),
5′-CCGCUUCACCAAAAGUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 356),
5′-CCGCUUCACCAAAAGCUUAGGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 357),
5′-CCGCUUCACCAAAAGCUUUAGAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 358),
5′-CCGCUUCACCAAAAGCUGUUAGUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 359),
5′-CCGCUUCACCAAAAGCUGUUAGUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 360),
5′-CCGCUUCACCAAAAGCUGUUUAGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 361),
5′-CCGCUUCACCAAAAGCUGUCUUAGGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 362), and
5′-CCGCUUCACCAAAAGCUGUCCCUUAGGGGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 11);
a sequence selected from the group consisting of 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUAACCCUCGA-3′ (SEQ ID NO: 434),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUUCGAAAGUAACCCUCGA-3′ (SEQ ID NO: 435),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUCGAAGUAACCCUCGA-3′ (SEQ ID NO: 436),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUCUUCGGAGUAACCCUCGA-3′ (SEQ ID NO: 437),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCGAGUAACCCUCGA-3′ (SEQ ID NO: 438),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUCGGUAACCCUCGA-3′ (SEQ ID NO: 439),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGUUCGUAACCCUCGA-3′ (SEQ ID NO: 440),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUUCGAACCCUCGA-3′ (SEQ ID NO: 441),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUCGACCCUCGA-3′ (SEQ ID NO: 442),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUCGCCCUCGA-3′ (SEQ ID NO: 443),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAUUCGCCCUCGA-3′ (SEQ ID NO: 444),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAUUCGCCUCGA-3′ (SEQ ID NO: 445),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAUUCGCCUCGA-3′ (SEQ ID NO: 446),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGUUCGCUCGA-3′ (SEQ ID NO: 447), and
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUAACCCUCGA-3′ (SEQ ID NO: 12);
a sequence selected from 5′-AACAAAGAAAGGA-3′ (SEQ ID NO: 111),
5′-AACAAAUGAAAAGGA-3′ (SEQ ID NO: 112),
5′-AACAAAUUGAAAAAGGA-3′ (SEQ ID NO: 113),
5′-AACAAAUUCGAAAGAAGGA-3′ (SEQ ID NO: 114),
5′-AACAAAUUCAGAAAUGAAGGA-3′ (SEQ ID NO: 115),
5′-AACAAAUUCAUGAAAAUGAAGGA-3′ (SEQ ID NO: 116),
5′-AACAAAUUCAUUGAAAAAUGAAGGA-3′ (SEQ ID NO: 117), and
5′-AACAAAUUCAUUUGAAAGAAUGAAGGA-3′ (SEQ ID NO: 118); and
5′-AUGCAAC-3′.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the dCas12f1 protein is a dCas12f1 R490A protein, a dCas12f1 R490Q protein, a dCas12f1 R490L protein, or a dCas12f1 R490W protein.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the dCas12f1 protein is a dCas12f1 D510A protein, a dCas12f1 D510L protein, or a dCas12f1 D510V protein.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the dCas12f1 protein is a dCas12f1 D326A protein or a dCas12f1 E422A protein.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the transcriptional inhibitor protein is a protein or peptide that inhibits or suppresses transcription of the target gene by blocking RNA polymerase from being attached to a promoter of the target gene or inducing a structural change in chromatin of the target gene.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the transcriptional inhibitor protein is KRAB, MeCP2, DNMT, LSD, or HDAC.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the transcriptional inhibitor Cas12f1 fusion protein further comprises at least one transcriptional inhibitor protein.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the transcriptional inhibitor protein is KRAB, MeCP2, DNMT, LSD, or HDAC.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the transcriptional inhibitor Cas12f1 fusion protein further comprises at least one NLS or NES.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the sequence of the U-rich tail is represented by 5′-UUUURUUUU-3′.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the sequence of the scaffold region included in the engineered Cas12f1 guide RNA is such that the following sequences are sequentially linked to each other in a 5′ to 3′ direction:
5′-A-3′;
(SEQ ID NO: 11)
5′-
CCGCUUCACCAAAAGCUGUCCCUUAGGGGAUUAGAACUUGAGUGAAG
GUGG-3′;
(SEQ ID NO: 12)
5′-
GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUA
ACCCUCGA-3′;
(SEQ ID NO: 111)
5′-AACCAAAGAAAGGA-3′;
and
5′-AUGCAAC-3′.

### Claim 12 (depends on 1)

The composition of claim 1, wherein a sequence of the scaffold region included in the engineered Cas12f1 guide RNA is such that the following sequences are sequentially linked to each other in a 5′ to 3′ direction:
5′-A-3′;
(SEQ ID NO: 350)
5′-CCGCUUCACUUAGAGUGAAGGUGG-3′;
(SEQ ID NO: 12)
5′-
GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAA
GUAACCCUCGA-3′;
(SEQ ID NO: 111)
5′-AACCAAAGAAAGGA-3′;
and
5′-AUGCAAC-3′.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the composition is in a form of a vector.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the composition further comprises promoters for the nucleic acid encoding the transcriptional inhibitor Cas12f1 fusion protein and the nucleic acid encoding the engineered Cas12f1 guide RNA.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the vector is at least one selected from the group consisting of a plasmid, a retrovirus, a lentivirus, an adenovirus, an adeno-associated virus, a vaccinia virus, a poxvirus, and a herpes simplex virus.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the composition is in a form of a ribonucleoprotein (RNP) in which the engineered Cas12f1 guide RNA and the transcriptional inhibitor Cas12f1 fusion protein are bound to each other.

### Claim 17

A method of inhibiting expression of a target gene in a cell, the method comprising
delivering, into a cell, a transcriptional inhibitor Cas12f1 fusion protein or a nucleic acid encoding the transcriptional inhibitor Cas12f1 fusion protein, and an engineered Cas12f1 guide RNA or a nucleic acid encoding the engineered Cas12f1 guide RNA,
which allows a CRISPR interference complex to be formed in the cell,
wherein the CRISPR interference complex is capable of suppressing transcription of the target gene,
the transcriptional inhibitor Cas12f1 fusion protein comprises a dead Cas12f1 (dCas12f1) protein and a transcriptional inhibitor protein,
the dCas12f1 protein is a modified form of a wild-type Cas12f1 protein in which aspartic acid (D) which is the 326th amino acid, glutamic acid (E) which is the 422nd amino acid, arginine (R) which is the 490th amino acid, or aspartic acid (D) which is the 510th amino acid in the amino acid sequence constituting the wild-type Cas12f1 protein is substituted with alanine (A), glutamine (Q), leucine (L), tryptophan (W), or valine (V), and
the transcriptional inhibitor protein is a protein or peptide that inhibits or suppresses transcription of the gene, and
wherein the engineered Cas12f1 guide RNA comprises:
an engineered scaffold region;
a spacer, and
a U-rich tail,
wherein the engineered scaffold region, the spacer, and the U-rich tail are sequentially linked to each other in a 5′ to 3′ direction,
the spacer comprises 10 to 50 nucleotides, and has a sequence complementary to the target sequence,
a sequence of the U-rich tail is represented by (UaN)bUc, wherein N is one of adenosine (A), uridine (U), cytidine (C), and guanosine (G), and a, b, c are each an integer, with a being between 1 to 5 inclusive, and b being 0 or greater,
a sequence of the engineered scaffold region is different from 5′-CUUCACUGAUAAAGUGGAGAACCGCUUCACCAAAAGCUGUCCCUUAGGGGAUUAGA ACUUGAGUGAAGGUGGGCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUCUU CGGAAAGUAACCCUCGAAACCAAAUUCAUUUGAAAGAAUGAAGGAAUGCAAC-3′ (SEQ ID NO: 7), and
the sequence of the engineered scaffold region is such that the following sequences are sequentially linked to each other in a 5′ to 3′ direction:
a sequence selected from the group consisting of 5′-A-3′, 5′-AA-3′, 5′-GAA-3′, 5′-AGAA-3′, 5′-GAGAA-3′, 5′-GGAGAA-3′, 5′-UGGAGAA-3′, 5′-GUGGAGAA-3′, 5′-AGUGGAGAA-3′, 5′-AAGUGGAGAA-3′ (SEQ ID NO: 17), 5′-AAAGUGGAGAA-3′ (SEQ ID NO: 18),
5′-UAAAGUGGAGAA-3′ (SEQ ID NO: 19),
5′-AUAAAGUGGAGAA-3′ (SEQ ID NO: 20),
5′-GAUAAAGUGGAGAA-3′ (SEQ ID NO: 21),
5′-UGAUAAAGUGGAGAA-3′ (SEQ ID NO: 22),
5′-CUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 23),
5′-ACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 24),
5′-CACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 25),
5′-UCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 26),
5′-UUCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 27), and
5′-CUUCACUGAUAAAGUGGAGAA-3′ (SEQ ID NO: 10);
a sequence selected from the group consisting of 5′-G-3′, 5′-UUAGG-3′, 5′-CUUAGGG-3′, 5′-CUUAGUGG-3′, 5′-CCUUAGGUGG-3′ (SEQ ID NO: 342), 5′-CCGUUAGGUGG-3′ (SEQ ID NO: 343), 5′-CCGCUUAGGGUGG-3′ (SEQ ID NO: 344),
5′-CCGCUUUAGAGGUGG-3′ (SEQ ID NO: 345),
5′-CCGCUUUUAGAAGGUGG-3′ (SEQ ID NO: 346),
5′-CCGCUUCUUAGGAAGGUGG-3′ (SEQ ID NO: 347),
5′-CCGCUUCAUUAGUGAAGGUGG-3′ (SEQ ID NO: 348),
5′-CCGCUUCACUUAGGUGAAGGUGG-3′ (SEQ ID NO: 349),
5′-CCGCUUCACUUAGAGUGAAGGUGG-3′ (SEQ ID NO: 350),
5′-CCGCUUCACCUUAGGAGUGAAGGUGG-3′ (SEQ ID NO: 351),
5′-CCGCUUCACCAUUAGUGAGUGAAGGUGG-3′ (SEQ ID NO: 352),
5′-CCGCUUCACCAAUUAGUUGAGUGAAGGUGG-3′ (SEQ ID NO: 353),
5′-CCGCUUCACCAAAUUAGCUUGAGUGAAGGUGG-3′ (SEQ ID NO: 354),
5′-CCGCUUCACCAAAAUUAGACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 355),
5′-CCGCUUCACCAAAAGUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 356),
5′-CCGCUUCACCAAAAGCUUAGGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 357),
5′-CCGCUUCACCAAAAGCUUUAGAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 358),
5′-CCGCUUCACCAAAAGCUGUUAGUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 359),
5′-CCGCUUCACCAAAAGCUGUUAGUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 360),
5′-CCGCUUCACCAAAAGCUGUUUAGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 361),
5′-CCGCUUCACCAAAAGCUGUCUUAGGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 362), and
5′-CCGCUUCACCAAAAGCUGUCCCUUAGGGGAUUAGAACUUGAGUGAAGGUGG-3′ (SEQ ID NO: 11);
a sequence selected from the group consisting of 5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUAACCCUCGA-3′ (SEQ ID NO: 434),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUUCGAAAGUAACCCUCGA-3′ (SEQ ID NO: 435),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUUCGAAGUAACCCUCGA-3′ (SEQ ID NO: 436),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUCUUCGGAGUAACCCUCGA-3′ (SEQ ID NO: 437),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCGAGUAACCCUCGA-3′ (SEQ ID NO: 438),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUCGGUAACCCUCGA-3′ (SEQ ID NO: 439),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGUUCGUAACCCUCGA-3′ (SEQ ID NO: 440),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUUCGAACCCUCGA-3′ (SEQ ID NO: 441),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUCGACCCUCGA-3′ (SEQ ID NO: 442),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUUCGCCCUCGA-3′ (SEQ ID NO: 443),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAUUCGCCCUCGA-3′ (SEQ ID NO: 444),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAUUCGCCUCGA-3′ (SEQ ID NO: 445),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAUUCGCCUCGA-3′ (SEQ ID NO: 446),
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGUUCGCUCGA-3′ (SEQ ID NO: 447), and
5′-GCUGCUUGCAUCAGCCUAAUGUCGAGAAGUGCUUUCUUCGGAAAGUAACCCUCGA-3′ (SEQ ID NO: 12);
a sequence selected from 5′-AACAAAGAAAGGA-3′ (SEQ ID NO: 111),
5′-AACAAAUGAAAAGGA-3′ (SEQ ID NO: 112),
5′-AACAAAUUGAAAAAGGA-3′ (SEQ ID NO: 113),
5′-AACAAAUUCGAAAGAAGGA-3′ (SEQ ID NO: 114),
5′-AACAAAUUCAGAAAUGAAGGA-3′ (SEQ ID NO: 115),
5′-AACAAAUUCAUGAAAAUGAAGGA-3′ (SEQ ID NO: 116),
5′-AACAAAUUCAUUGAAAAAUGAAGGA-3′ (SEQ ID NO: 117), and
5′-AACAAAUUCAUUUGAAAGAAUGAAGGA-3′ (SEQ ID NO: 118); and
5′-AUGCAAC-3′.

### Claim 18 (depends on 17)

The method of claim 17, wherein the delivery is achieved by introducing, into the cell, the transcriptional inhibitor Cas12f1 fusion protein and the engineered Cas12f1 guide RNA as a CRISPR interference complex.

### Claim 19 (depends on 17)

The method of claim 17, wherein the delivery is achieved by introducing, into the cell, a vector that comprises the nucleic acid encoding the transcriptional inhibitor Cas12f1 fusion protein and the nucleic acid encoding the engineered Cas12f1 guide RNA.

### Claim 20 (depends on 19)

The method of claim 19, wherein the vector is a plasmid vector or a viral vector.

### Claim 21 (depends on 20)

The method of claim 20, wherein the viral vector is at least one selected from the group consisting of a retrovirus, a lentivirus, an adenovirus, an adeno-associated virus, a vaccinia virus, a poxvirus, and a herpes simplex virus.

### Claim 22 (depends on 17)

The method of claim 17, wherein the cell is a eukaryotic cell.
